Ceriani CEJ, Willhour DA, Silberstein SD. 2019. Novel medications for the treatment of migraine. J Head and Face Pain [review]. 59(9): 1597-1608.
Charles A, Pozo-Rosich P. 2019. Targeting calcitocin gene-related peptide: a new era in migraine therapy. The Lancet. 394: 7165-1774.
Hargreaves R, Olesen J. 2019. Calcitocin gene-related peptide modulators -- the history and renaissance of a new migraine drug class. J Headache and Face Pain. 59(6): 951-970.
Lipton RB. Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. 2019. Rimegepant, an oral calcitocin gene-related peptide receptor antagonist, for migraine. New England Journal of Medicine. 381(2): 142-149.
Loder E. 2010. Triptan therapy in migraine. New England Journal of Medicine. 363(1): 63-70.
Moreno-Ajona D, Perez-Rodriguez A, Goadsby PJ. 2020. Gepants, calcitocin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? [review]. Current Opinion in Neurology. 33(3): 309-315.
Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Marterlletti P. 2019. European headache federation guideline on the use of monoclonal antibodies acting on the calcitocin gene related peptide or its receptor for migraine prevention. J Headache and Pain. 20(1): 1-33.
Baca konten-konten menarik Kompasiana langsung dari smartphone kamu. Follow channel WhatsApp Kompasiana sekarang di sini: https://whatsapp.com/channel/0029VaYjYaL4Spk7WflFYJ2H
